Skip to content
+49 3371 6199600info@celltrend.deIm Biotechnologiepark 3 TGZ II, 14943 Luckenwalde
  • Contact
  • German
  • English
topbar - English
Search:
Suche
CellTrend Luckenwalde
Auftragsforschung, Antikörperdiagnostik
CellTrend LuckenwaldeCellTrend Luckenwalde
  • Company Profile
    • Newsroom
    • Board of management
    • Quality Management System
    • Referenzen
    • Partners
  • POTS–CFS/ME–SFN-Long Covid
    • Information for patients
  • ELISA
    • AT1R-Antibody ELISA
      • Product information
      • Transplantation
      • Systemic sclerosis
      • Literature
    • GPCR-Antibodies
    • In vitro Diagnostics (human)
    • Research use only
    • Food analysis
    • Contract research
    • Contract manufacturing
  • Consulting
  • Fluorescent Cells
  • Cell culture test systems
    • Oncology
    • Inflammatory test systems
    • Contract research
  • Ordering ELISA Kits
  • Company Profile
    • Newsroom
    • Board of management
    • Quality Management System
    • Referenzen
    • Partners
  • POTS–CFS/ME–SFN-Long Covid
    • Information for patients
  • ELISA
    • AT1R-Antibody ELISA
      • Product information
      • Transplantation
      • Systemic sclerosis
      • Literature
    • GPCR-Antibodies
    • In vitro Diagnostics (human)
    • Research use only
    • Food analysis
    • Contract research
    • Contract manufacturing
  • Consulting
  • Fluorescent Cells
  • Cell culture test systems
    • Oncology
    • Inflammatory test systems
    • Contract research
  • Ordering ELISA Kits

recommendation NINDS

You are here:
  1. Home
  2. News
  3. recommendation NINDS

The US National Institute of Neurological Disorders and Stroke (NINDS), one of the most renowned neuroscience research institutes, has included our antibody determinations in its recommendations for the diagnosis of CFS / ME.

F2765_Laboratory_Tests_Immune_Module.pdf (291,0 KiB)

2. July 2018

News
  • News from Prof. Dr. Scheibenbogen about Autoantibody Study in the “Tagesspiegel” 21. May 2025
  • ME/CFS Conference 2025 in Berlin 17. May 2025
  • New findings of Autoantibodies targeting GPCR in Sjögren´s Syndrome 5. May 2025
  • AONM is the new partner for CellTrends Antibodies in England and Ireland 24. April 2025
  • CellTrend supports the project fire safety book for children 17. April 2025
  • Price adjustment 9. April 2025
+49 3371 6199600 info@celltrend.de Im Biotechnologiepark 3 TGZ II, 14943 Luckenwalde
  • Data protection declaration
  • Imprint
bottombar - English

FacebookInstagram

Go to Top
Um unsere Webseite für Sie optimal zu gestalten und fortlaufend zu verbessern, verwenden wir Cookies. Durch die weitere Nutzung der Webseite stimmen Sie deren Verwendung zu. Weitere Informationen erhalten Sie in unserer DatenschutzerklärungOK